A subgroup analysis (n=12) of the COMPACT study, on patients that received IV C1INH at baseline, found that switching from C1INH IV LTP to SC C1INH LTP resulted in a reduction in HAE attack rate of 53.7% (11). This evidence concerns the gene SERPING1 and hereditary angioedema.